Osimertinib combined with anlotinib as first-line treatment in advanced or metastatic NSCLC patients with EGFR mutation: a prospective, single arm, exploratory study
Titel:
Osimertinib combined with anlotinib as first-line treatment in advanced or metastatic NSCLC patients with EGFR mutation: a prospective, single arm, exploratory study
Auteur:
Yan, Bo Zhang, Bo Chu, Tianqing Zhang, Wei Shi, Chunlei Wang, Huimin Zhang, Xueyan Han, Baohui Zhong, Hua